{"id":60157,"date":"2026-03-20T13:47:16","date_gmt":"2026-03-20T05:47:16","guid":{"rendered":"https:\/\/flcube.com\/?p=60157"},"modified":"2026-03-20T13:47:17","modified_gmt":"2026-03-20T05:47:17","slug":"3sbio-wins-nmpa-approval-for-sss06-extended-half-life-erythropoietin-enables-biweekly-dosing-in-dialysis-anemia","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=60157","title":{"rendered":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia"},"content":{"rendered":"\n<p><strong>3SBio Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1530:HKG\">HKG: 1530<\/a>) announced that China&#8217;s <strong>National Medical Products Administration (NMPA)<\/strong> has approved <strong>SSS06<\/strong>, a <strong>glycosylated recombinant erythropoietin protein<\/strong>, for <strong>anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy<\/strong> \u2013 offering a <strong>&#8220;once every two weeks&#8221; dosing regimen<\/strong> through optimized protein stability and extended in vivo half\u2011life.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Agency<\/strong><\/td><td>NMPA (China)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>SSS06 \u2013 glycosylated recombinant erythropoietin<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>3SBio Inc. (HKG: 1530)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Anemia caused by chronic kidney disease in hemodialysis patients<\/td><\/tr><tr><td><strong>Dosing Advantage<\/strong><\/td><td><strong>Once every two weeks<\/strong> (extended half\u2011life vs. traditional EPO)<\/td><\/tr><tr><td><strong>Approval Basis<\/strong><\/td><td>Phase III non\u2011inferiority study<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-amp-technology-innovation\">Product Profile &amp; Technology Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>Glycosylated recombinant erythropoietin (EPO)<\/strong><\/li>\n\n\n\n<li><strong>Engineering Innovation:<\/strong> <strong>Precisely increased glycosylation sites<\/strong><\/li>\n\n\n\n<li><strong>Pharmacokinetic Benefit:<\/strong><\/li>\n\n\n\n<li><strong>Optimized protein stability<\/strong><\/li>\n\n\n\n<li><strong>Significantly extended in vivo half\u2011life<\/strong><\/li>\n\n\n\n<li><strong>Retained biological activity<\/strong><\/li>\n\n\n\n<li><strong>Clinical Advantage:<\/strong> <strong>Biweekly (Q2W) dosing<\/strong> vs. traditional EPO requiring 2\u20113x weekly administration \u2013 improved patient convenience and adherence<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-phase-iii-clinical-evidence\">Phase III Clinical Evidence<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>SSS06 Result<\/th><th>Control (Yibiao \u2013 rhEPO)<\/th><th>Conclusion<\/th><\/tr><\/thead><tbody><tr><td><strong>Hemoglobin Maintenance<\/strong><\/td><td>Maintained Hb concentration<\/td><td>Maintained Hb concentration<\/td><td><strong>Non\u2011inferiority confirmed<\/strong><\/td><\/tr><tr><td><strong>Efficacy Comparison<\/strong><\/td><td>No significant difference<\/td><td>\u2013<\/td><td>SSS06 comparable to standard rhEPO<\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Adverse event incidence\/severity<\/td><td>Comparable AE profile<\/td><td><strong>No new safety signals<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Study Design:<\/strong> Phase III maintenance treatment efficacy verification in hemodialysis patients with CKD anemia<\/li>\n\n\n\n<li><strong>Comparator:<\/strong> Yibiao (recombinant human erythropoietin) \u2013 established standard of care<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context-amp-strategic-positioning\">Market Context &amp; Strategic Positioning<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Dimension<\/th><th>CKD Anemia Market<\/th><th>SSS06 Position<\/th><\/tr><\/thead><tbody><tr><td><strong>Market Size<\/strong><\/td><td>China ~2 million hemodialysis patients; anemia affects &gt;90%<\/td><td>Large addressable population with unmet need for simplified dosing<\/td><\/tr><tr><td><strong>Current Standard<\/strong><\/td><td>Short\u2011acting rhEPO (2\u20113x weekly); darbepoetin alfa (Aranesp) weekly\/biweekly<\/td><td>SSS06 offers biweekly dosing with potentially lower cost vs. imported long\u2011acting EPO<\/td><\/tr><tr><td><strong>Competitive Landscape<\/strong><\/td><td>3SBio established EPO player (Yibiao, Epiao); Roche (Mircera), Amgen (Aranesp) in premium segment<\/td><td>SSS06 extends 3SBio&#8217;s EPO franchise with next\u2011generation glycoengineering<\/td><\/tr><tr><td><strong>Pricing Advantage<\/strong><\/td><td>Domestic manufacturing cost structure vs. imported long\u2011acting EPOs<\/td><td>Potential for NRDL (National Reimbursement Drug List) inclusion at accessible pricing<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-outlook\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>CKD Anemia Market Dynamics:<\/strong> China hemodialysis population growing <strong>8\u201110% annually<\/strong> driven by diabetes\/hypertension epidemics; EPO market estimated <strong>RMB3\u20114 billion<\/strong> annually with shift toward long\u2011acting formulations for improved adherence and reduced nursing burden.<\/li>\n\n\n\n<li><strong>3SBio Portfolio Synergies:<\/strong> SSS06 joins established EPO franchise (Yibiao, Epiao, SSS04); glycoengineering platform validated for biologics lifecycle management; potential for SSS06 label expansion to peritoneal dialysis and chemotherapy\u2011induced anemia.<\/li>\n\n\n\n<li><strong>Clinical Adoption Trajectory:<\/strong> Biweekly dosing addresses <strong>nursing resource constraints<\/strong> in busy dialysis centers and <strong>patient preference<\/strong> for reduced injection frequency; expected to capture <strong>20\u201130% of 3SBio&#8217;s EPO volume<\/strong> within 3 years of launch assuming NRDL pricing.<\/li>\n\n\n\n<li><strong>Manufacturing &amp; Supply:<\/strong> 3SBio&#8217;s Shenyang biologics manufacturing base supports SSS06 production; glycosylation optimization requires specialized cell culture capabilities; capacity expansion likely to meet anticipated demand.<\/li>\n\n\n\n<li><strong>Regulatory Expansion Potential:<\/strong> NMPA approval provides reference for <strong>ex\u2011China submissions<\/strong> in emerging markets (Southeast Asia, Latin America, Middle East) where 3SBio has established biosimilar presence; US\/EU regulatory pathway challenging given originator patent landscape.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding commercialization timelines, market share projections, and pricing expectations for SSS06. Actual results may differ due to NRDL negotiation outcomes, competitive responses from long\u2011acting EPO manufacturers, and manufacturing scale\u2011up efficiency.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>3SBio Inc. (HKG: 1530) announced that China&#8217;s National Medical Products Administration (NMPA) has approved SSS06,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":60159,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[116,1061,15],"class_list":["post-60157","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-3sbio","tag-hkg-1530","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"3SBio Inc. (HKG: 1530) announced that China&#039;s National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a &quot;once every two weeks&quot; dosing regimen through optimized protein stability and extended in vivo half\u2011life.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=60157\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia\" \/>\n<meta property=\"og:description\" content=\"3SBio Inc. (HKG: 1530) announced that China&#039;s National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a &quot;once every two weeks&quot; dosing regimen through optimized protein stability and extended in vivo half\u2011life.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=60157\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-20T05:47:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-20T05:47:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia\",\"datePublished\":\"2026-03-20T05:47:16+00:00\",\"dateModified\":\"2026-03-20T05:47:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157\"},\"wordCount\":538,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2005.webp\",\"keywords\":[\"3SBio\",\"HKG: 1530\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60157#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=60157\",\"name\":\"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2005.webp\",\"datePublished\":\"2026-03-20T05:47:16+00:00\",\"dateModified\":\"2026-03-20T05:47:17+00:00\",\"description\":\"3SBio Inc. (HKG: 1530) announced that China's National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a \\\"once every two weeks\\\" dosing regimen through optimized protein stability and extended in vivo half\u2011life.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=60157\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2005.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/2005.webp\",\"width\":1080,\"height\":608,\"caption\":\"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=60157#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia - Insight, China&#039;s Pharmaceutical Industry","description":"3SBio Inc. (HKG: 1530) announced that China's National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a \"once every two weeks\" dosing regimen through optimized protein stability and extended in vivo half\u2011life.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=60157","og_locale":"en_US","og_type":"article","og_title":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia","og_description":"3SBio Inc. (HKG: 1530) announced that China's National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a \"once every two weeks\" dosing regimen through optimized protein stability and extended in vivo half\u2011life.","og_url":"https:\/\/flcube.com\/?p=60157","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-20T05:47:16+00:00","article_modified_time":"2026-03-20T05:47:17+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=60157#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=60157"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia","datePublished":"2026-03-20T05:47:16+00:00","dateModified":"2026-03-20T05:47:17+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=60157"},"wordCount":538,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=60157#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","keywords":["3SBio","HKG: 1530","Product approvals"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=60157#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=60157","url":"https:\/\/flcube.com\/?p=60157","name":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=60157#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=60157#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","datePublished":"2026-03-20T05:47:16+00:00","dateModified":"2026-03-20T05:47:17+00:00","description":"3SBio Inc. (HKG: 1530) announced that China's National Medical Products Administration (NMPA) has approved SSS06, a glycosylated recombinant erythropoietin protein, for anemia treatment in chronic kidney disease (CKD) patients under hemodialysis and erythropoietin therapy \u2013 offering a \"once every two weeks\" dosing regimen through optimized protein stability and extended in vivo half\u2011life.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=60157#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=60157"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=60157#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","width":1080,"height":608,"caption":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=60157#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"3SBio Wins NMPA Approval for SSS06 \u2013 Extended\u2011Half\u2011Life Erythropoietin Enables Biweekly Dosing in Dialysis Anemia"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/2005.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60157","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=60157"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60157\/revisions"}],"predecessor-version":[{"id":60160,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/60157\/revisions\/60160"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/60159"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=60157"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=60157"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=60157"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}